Tenofovir alafenamide: An effective option for HIV treatment with reduced risk

Darren Wong, Robert M. Grossberg

Research output: Contribution to journalArticle

Abstract

Tenofovir disoproxil fumarate has rapidly become an integral part of HIV antiretroviral regimens throughout the world. The advancement of increasingly effective therapeutics has led to a new frontier in HIV treatment, notably the search for options that retain high potency but improved tolerability and long-term safety profiles. Tenofovir alafenamide is a new investigational prodrug developed by Gilead Sciences, Inc. Tenofovir alafenamide has enhanced tissue distribution, specifically into lymphoid tissue, providing increased delivery of active drug to the target site of viral replication. This property may enhance drug activity and allow for a lower required oral administered dose, lower plasma drug levels and reduced adverse effects on the kidney and bone.

Original languageEnglish (US)
Pages (from-to)1069-1075
Number of pages7
JournalFuture Virology
Volume10
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Tenofovir
HIV
Pharmaceutical Preparations
Prodrugs
Lymphoid Tissue
Tissue Distribution
Kidney
Safety
Bone and Bones
GS-7340
Therapeutics

Keywords

  • antiretroviral
  • HBV
  • HIV
  • tenofovir

ASJC Scopus subject areas

  • Virology

Cite this

Tenofovir alafenamide : An effective option for HIV treatment with reduced risk. / Wong, Darren; Grossberg, Robert M.

In: Future Virology, Vol. 10, No. 9, 01.09.2015, p. 1069-1075.

Research output: Contribution to journalArticle

@article{6b252ba962f04f1b81f1e332cd8614ea,
title = "Tenofovir alafenamide: An effective option for HIV treatment with reduced risk",
abstract = "Tenofovir disoproxil fumarate has rapidly become an integral part of HIV antiretroviral regimens throughout the world. The advancement of increasingly effective therapeutics has led to a new frontier in HIV treatment, notably the search for options that retain high potency but improved tolerability and long-term safety profiles. Tenofovir alafenamide is a new investigational prodrug developed by Gilead Sciences, Inc. Tenofovir alafenamide has enhanced tissue distribution, specifically into lymphoid tissue, providing increased delivery of active drug to the target site of viral replication. This property may enhance drug activity and allow for a lower required oral administered dose, lower plasma drug levels and reduced adverse effects on the kidney and bone.",
keywords = "antiretroviral, HBV, HIV, tenofovir",
author = "Darren Wong and Grossberg, {Robert M.}",
year = "2015",
month = "9",
day = "1",
doi = "10.2217/fvl.15.72",
language = "English (US)",
volume = "10",
pages = "1069--1075",
journal = "Future Virology",
issn = "1746-0794",
publisher = "Future Medicine Ltd.",
number = "9",

}

TY - JOUR

T1 - Tenofovir alafenamide

T2 - An effective option for HIV treatment with reduced risk

AU - Wong, Darren

AU - Grossberg, Robert M.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Tenofovir disoproxil fumarate has rapidly become an integral part of HIV antiretroviral regimens throughout the world. The advancement of increasingly effective therapeutics has led to a new frontier in HIV treatment, notably the search for options that retain high potency but improved tolerability and long-term safety profiles. Tenofovir alafenamide is a new investigational prodrug developed by Gilead Sciences, Inc. Tenofovir alafenamide has enhanced tissue distribution, specifically into lymphoid tissue, providing increased delivery of active drug to the target site of viral replication. This property may enhance drug activity and allow for a lower required oral administered dose, lower plasma drug levels and reduced adverse effects on the kidney and bone.

AB - Tenofovir disoproxil fumarate has rapidly become an integral part of HIV antiretroviral regimens throughout the world. The advancement of increasingly effective therapeutics has led to a new frontier in HIV treatment, notably the search for options that retain high potency but improved tolerability and long-term safety profiles. Tenofovir alafenamide is a new investigational prodrug developed by Gilead Sciences, Inc. Tenofovir alafenamide has enhanced tissue distribution, specifically into lymphoid tissue, providing increased delivery of active drug to the target site of viral replication. This property may enhance drug activity and allow for a lower required oral administered dose, lower plasma drug levels and reduced adverse effects on the kidney and bone.

KW - antiretroviral

KW - HBV

KW - HIV

KW - tenofovir

UR - http://www.scopus.com/inward/record.url?scp=84942575771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942575771&partnerID=8YFLogxK

U2 - 10.2217/fvl.15.72

DO - 10.2217/fvl.15.72

M3 - Article

AN - SCOPUS:84942575771

VL - 10

SP - 1069

EP - 1075

JO - Future Virology

JF - Future Virology

SN - 1746-0794

IS - 9

ER -